ストックスクリーナーアプリを入手
344.97
10.87%
33.83
Madrigal Pharmaceuticals Inc (MDGL) 最新ニュース
When (MDGL) Moves Investors should Listen - news.stocktradersdaily.com
Madrigal Pharmaceuticals Surges to 222nd in Daily Rankings with $451 Million Turnover - AInvest
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Madrigal Pharmaceuticals stock price target raised by Oppenheimer on patent news - Investing.com Canada
Madrigal’s Surge: Breakthrough in Liver Treatment? - timothysykes.com
Madrigal Pharmaceuticals (MDGL) Soars on Rezdiffra Patent Approval - GuruFocus
Madrigal gains after Rezdiffra patent win (MDGL:NASDAQ) - Seeking Alpha
Madrigal stock jumps as patent protection for MASH treatment extended By Investing.com - Investing.com Nigeria
Madrigal stock jumps as patent protection for MASH treatment extended - Investing.com
Madrigal receives patent allowance for MASH treatment Rezdiffra By Investing.com - Investing.com India
Why Madrigal Pharmaceuticals Inc. stock attracts strong analyst attentionFree Stock Investment Growth Plan - beatles.ru
Madrigal Pharmaceuticals (MDGL) Secures Patent for Rezdiffra Use - GuruFocus
Madrigal Pharmaceuticals Announces FDA Patent Allowance for Rezdiffra™ Providing Protection Through September 2044 - Quiver Quantitative
Madrigal Pharmaceuticals Receives Notice of Allowance from - GlobeNewswire
Madrigal Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for New U.S. Patent Covering Rezdiffra™ (Resmetirom) - Yahoo Finance
Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Shift From Loss To Profit - 富途牛牛
Loss-Making Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Expected To Breakeven In The Medium-Term - simplywall.st
MDGL Makes Notable Cross Below Critical Moving Average - Nasdaq
Madrigal Pharmaceuticals’ SWOT analysis: rezdiffra’s strong launch propels stock outlook - Investing.com
JMP Reaffirms Price Target for Madrigal Amid Rezdiffra Growth Potential - Yahoo Finance
Madrigal Pharmaceuticals (MDGL) Sees Stock Surge After Competito - GuruFocus
Altimmune’s phase IIb in MASH hits and misses, stock halves - BioWorld MedTech
Madrigal Pharmaceuticals Closer to EU Approval for First MASH Treatment, Rezdiffra - Yahoo Finance
Madrigal Pharmaceuticals: GLP-1s Inch Closer To MASH Market As REZDIFFRA Outperform (MDGL) - Seeking Alpha
Madrigal Pharmaceuticals Receives Positive CHMP Opinion for Resmetirom in Treating MASH - MyChesCo
Resmetirom's EU Approval Milestone Positions Madrigal as NASH Market Leader - AInvest
EMA Nod For First MASH Drug Rezdiffra, Cell Therapy Zemcelpro And 11 Others - insights.citeline.com
Madrigal Pharmaceuticals Awards Equity Grants to New Employees Under 2023 Inducement Plan - MSN
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | MDGL Stock News - GuruFocus
EU Decision Time For Madrigal’s MASH Drug Resmetirom And 11 Others - insights.citeline.com
(MDGL) Investment Analysis - news.stocktradersdaily.com
Madrigal Pharmaceuticals to Present at 46th Annual Goldman Sachs Health Care Conference - MSN
Transcript : Madrigal Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 10 - MarketScreener
Madrigal Pharmaceuticals Breaks Above 200-Day Moving AverageBullish for MDGL - Nasdaq
Cantor Fitzgerald Predicts MDGL FY2026 Earnings - Defense World
Head-To-Head Survey: Larimar Therapeutics (NASDAQ:LRMR) vs. Madrigal Pharmaceuticals (NASDAQ:MDGL) - Defense World
Reviewing Sonnet BioTherapeutics (NASDAQ:SONN) and Madrigal Pharmaceuticals (NASDAQ:MDGL) - Defense World
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
(MDGL) On The My Stocks Page - news.stocktradersdaily.com
Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference - GlobeNewswire
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Stake Lowered by Ameriprise Financial Inc. - Defense World
Roivant Staying ‘Patient’ On Deals, Leaving Investors Waiting - insights.citeline.com
Madrigal Pharmaceuticals’ SWOT analysis: rezdiffra’s promise drives stock outlook - Investing.com
Madrigal Pharmaceuticals’ SWOT analysis: rezdiffra’s promise drives stock outlook By Investing.com - Investing.com UK
Cetera Investment Advisers Has $889,000 Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - Defense World
In Search Of Tailwind, Sailing Doldrums With Madrigal Pharmaceuticals Stock (MDGL) - Seeking Alpha
A Short History Of MASH Deals, Culminating In GSK/Boston Pharma - insights.citeline.com
Will Other Major MASH Deals Follow GSK/Boston Pharma? - insights.citeline.com
2 Monster Stocks in the Making to Buy Now and Hold for 10 Years - AOL.com
Transcript : Madrigal Pharmaceuticals, Inc.Special Call - marketscreener.com
Where are the Opportunities in (MDGL) - news.stocktradersdaily.com
Madrigal Pharmaceuticals Reports Promising Two-Year Data for Rezdiffra in MASH Cirrhosis - MSN
Madrigal Pharma Short Interest Reaches 4-Month High: Retail Investors Still Bullish On Stock - MSN
MDGL Stock Gains on Positive Phase 3 Trial Results for Rezdiffra - GuruFocus
MDGL Stock Gains on Positive Phase 3 Trial Results for Rezdiffra | MDGL Stock News - GuruFocus
Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis - The Manila Times
Madrigal Says New Clinical Data Demonstrating Rezdiffra Significantly Improved Multiple Noninvasive Tests & Portal Hypertension Risk In Patients With Compensated Mash Cirrhosis - marketscreener.com
Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis - GlobeNewswire Inc.
3.40%
2.49%
大文字化:
|
ボリューム (24 時間):